Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen:
https://hdl.handle.net/10419/46451
Kompletter Metadatensatz
DublinCore-Feld | Wert | Sprache |
---|---|---|
dc.contributor.author | Brekke, Kurt R. | en |
dc.contributor.author | Holmås, Tor Helge | en |
dc.contributor.author | Straume, Odd Rune | en |
dc.date.accessioned | 2010-12-13 | - |
dc.date.accessioned | 2011-06-29T11:19:22Z | - |
dc.date.available | 2011-06-29T11:19:22Z | - |
dc.date.issued | 2010 | - |
dc.identifier.uri | http://hdl.handle.net/10419/46451 | - |
dc.description.abstract | We study the impact of regulation on competition between brand-names and generics and pharmaceutical expenditures using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample of off-patent products. First, we construct a vertical differentiation model to analyze the impact of regulation on prices and market shares of brand-names and generics. Then, we exploit a detailed panel data set at product level covering several off-patent molecules before and after the policy reform. Off-patent drugs not subject to RP serve as our control group. We find that RP significantly reduces both brand-name and generic prices, and results in significantly lower brand-name market shares. Finally, we show that RP has a strong negative effect on average molecule prices, suggesting significant cost-savings, and that patients' copayments decrease despite the extra surcharges under RP. | en |
dc.language.iso | eng | en |
dc.publisher | |aCenter for Economic Studies and ifo Institute (CESifo) |cMunich | en |
dc.relation.ispartofseries | |aCESifo Working Paper |x3258 | en |
dc.subject.jel | I11 | en |
dc.subject.jel | I18 | en |
dc.subject.jel | L13 | en |
dc.subject.jel | L65 | en |
dc.subject.ddc | 330 | en |
dc.subject.keyword | pharmaceuticals | en |
dc.subject.keyword | regulation | en |
dc.subject.keyword | generic competition | en |
dc.subject.stw | Pharmazeutisches Produkt | en |
dc.subject.stw | Staatliche Preispolitik | en |
dc.subject.stw | Preiswettbewerb | en |
dc.subject.stw | Produktdifferenzierung | en |
dc.subject.stw | Generika | en |
dc.subject.stw | Gesundheitskosten | en |
dc.subject.stw | Norwegen | en |
dc.title | Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment | - |
dc.type | Working Paper | en |
dc.identifier.ppn | 641609000 | en |
dc.rights | http://www.econstor.eu/dspace/Nutzungsbedingungen | en |
Datei(en):
Publikationen in EconStor sind urheberrechtlich geschützt.